6wkm
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wkm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wkm OCA], [https://pdbe.org/6wkm PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wkm RCSB], [https://www.ebi.ac.uk/pdbsum/6wkm PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wkm ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6wkm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6wkm OCA], [https://pdbe.org/6wkm PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6wkm RCSB], [https://www.ebi.ac.uk/pdbsum/6wkm PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6wkm ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Lymphocyte activation gene 3 protein (LAG3) is an inhibitory receptor that is upregulated on exhausted T cells in tumors. LAG3 is a major target for cancer immunotherapy with many anti-LAG3 antibodies in clinical trials. However, there is no structural information on the epitopes recognized by these antibodies. We determined the single-particle cryoEM structure of a therapeutic antibody (favezelimab) bound to LAG3 to 3.5 A resolution, revealing that favezelimab targets the LAG3-binding site for MHC class II, its canonical ligand. The small size of the complex between the conventional (monovalent) Fab of favezelimab and LAG3 ( approximately 100 kDa) presented a challenge for cryoEM. Accordingly, we engineered a bivalent version of Fab favezelimab that doubled the size of the Fab-LAG3 complex and conferred a highly identifiable shape to the complex that facilitated particle selection and orientation for image processing. This study establishes bivalent Fabs as new fiducial markers for cryoEM analysis of small proteins. | ||
| + | |||
| + | CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker.,Mishra AK, Shahid S, Karade SS, Agnihotri P, Kolesnikov A, Hasan SS, Mariuzza RA Structure. 2023 Oct 5;31(10):1149-1157.e3. doi: 10.1016/j.str.2023.07.013. Epub , 2023 Aug 23. PMID:37619561<ref>PMID:37619561</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6wkm" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
Current revision
Fab Fragment of Anti-human LAG3 antibody (22D2)
| |||||||||||
